M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership pharminent June 4, 2026
M&A / Deals Travere beefs up rare kidney disease portfolio with up to $1.1B China deal pharminent June 3, 2026
M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026
M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments pharminent June 2, 2026
M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn pharminent June 2, 2026
M&A / Deals CordenPharma inks AmbioPharm buyout to continue peptide production expansion pharminent June 1, 2026
M&A / Deals Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent pharminent May 29, 2026
M&A / Deals Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss pharminent May 27, 2026
M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026
M&A / Deals Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling pharminent May 21, 2026
M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates pharminent May 19, 2026
M&A / Deals Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B pharminent May 18, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
M&A / Deals Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion pharminent May 12, 2026
